GlobeNewswire by notified

Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership

Share

RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership.  Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services backed by comprehensive capabilities and cutting-edge, fully-licensed technologies.

Custom animal models play a critical role in new drug discovery as biological systems that provide critical insight into the dynamic between a potential therapeutic and a living organism.

Combining over twenty years of experience, the industry's most extensive model generation technology portfolio, and seamless integration to downstream premium custom breeding solutions, Taconic is recognized for creating complex genetically engineered mice and rats for biomedical research. Cyagen entered the industry in 2005 and has gained a strong following for providing model and vector generation services. Through the alliance, Cyagen customers gain access to expanded expertise, comprehensive program management, state-of-the art technologies, pricing flexibility, and faster project timelines through a single point of contact, ensuring the best solution for each unique project. 

"Taconic will provide the best solution to every model generation customer through access to scientific experts who generate superior designs using state-of-the-art methods.  Through this alliance with Cyagen, Taconic can now offer customers the broadest range of options in the industry in line with market demand," shared Dr. Robert Rosenthal, CEO of Taconic Biosciences. 

"Cyagen Biosciences provides researchers with the highest quality animal models possible to ensure ground breaking discoveries.  Researchers are increasingly demanding higher quality animal model services at lower costs. Through this new alliance with Taconic, Cyagen will offer researchers even higher quality animal models, with new options available to minimize or eliminate quarantine and other added costs, while providing production capabilities that exceed previous standards and expectations," commented Dr. Reza Rezaei, VP of Sales of Cyagen Biosciences.

To learn more about Taconic Biosciences' products and services, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

To learn more about Cyagen Biosciences, please call 800-921-8930 (from 8 a.m. - 6 p.m. PST) or +1-408-969-0306 (Int'l) in the US, 800-793-45 or +32-28085797 (Int'l) in Europe, or email service@cyagen.com.

About Cyagen Biosciences, Inc.
Cyagen Biosciences is the world's largest provider of custom-engineered mouse & rat models. Cyagen is world renowned for its quality, money back guarantee, and cost-effective prices. Headquartered in California, with locations in Germany, Japan, and China, Cyagen provides researchers from around the world with transgenic, knockout, knock-in, CRISPR, and ES-cell based models and also offers a comprehensive series of stem cell products for research use, including cell lines, media, and differentiation kits. From vector and strategy design to animal model creation, cryopreservation, and breeding, Cyagen offers complete outsourcing for all animal model needs.

About Taconic Biosciences, Inc.
Taconic Biosciences is a global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal model solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience, providing gene inactivation, gene mutation, replacement and humanization, transgene expression, RNAi, and gene editing via CRISPR/Cas9 technologies to ensure that the right tools are leveraged for each specific customer project.  Complimenting this expertise is Taconic's unique capability of providing a seamless transition from model design to breeding and colony management, thus offering customers a complete solution.  Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
Taconic Biosciences 
(518) 697-3824
kelly.grover@taconic.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May25.4.2024 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating activities of CHF 47.6 million (2022: CHF -29.8 million)Regulatory approvals in key territories – AGAMREE® (vamorolone) approved for Duchenne muscular dystrophy (DMD) treatment in the U.S., EU and UK, showcasing safety benefits over traditional corticosteroidsStrategic partnership – licensing agreement signed with Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) for North America, focusing on commercialization of AGAMREE in DMD and exploring joint development of indications beyond DMDFirst launches

Verkkokauppa.com focused on profitability in a declining market25.4.2024 07:00:00 CEST | Press release

INTERIM REPORT for 1 January – 31 March 2024 VERKKOKAUPPA.COM FOCUSED ON PROFITABILITY IN A DECLINING MARKET Verkkokauppa.com Oyj INTERIM REPORT 25 April 2024, 8:00 a.m. EEST Verkkokauppa.com arranges two virtual news conferences on a result publication day. The news conference in Finnish will be held at 10:00 am Finnish time. The news conference for analysts and institutional investors in English will be at 11:00 am Finnish time. Details of the events and how to participate can be found at the end of this release. This is a summary of Verkkokauppa.com’s Financial Statements Review for 1 January – 31 December 2023. The complete report is attached to this release and also available at https://investors.verkkokauppa.com/en Unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures are unaudited. January – March 2024 in brief Revenue was EUR 108.0 million (122.0)Gross profit was EUR 18.7 million (20.2) or

Kitron: Q1 2024 - Sterk underliggende lønnsomhet i utfordrende marked25.4.2024 07:00:00 CEST | Pressemelding

(2024-04-25) Kitron rapporterer i dag sterk underliggende lønnsomhet i et utfordrende marked. Det gjennomføres kostnadstiltak for å opprettholde driftsmarginer i tråd med selskapets strategiske mål. Kitrons driftsinntekter for første kvartal var 173,9 millioner euro, sammenlignet med 190,6 millioner i fjor. Det var sterk vekst innenfor markedssektoren Forsvar/Luftfart, mens andre markedssektorer viste nedgang. Driftsresultatet (EBIT) i første kvartal var 10,6 millioner euro, sammenlignet med 17,3 millioner i fjor. EBITDA ble 15,2 millioner euro, mot 21,4 millioner i fjor. Resultatet er påvirket av restruktureringskostnader på 4,8 millioner euro. Lønnsomheten uttrykt som EBIT-margin var 6,1 prosent, inkludert restruktureringskostnadene, mot 9,1 prosent i fjor. Lønnsomheten justert for restruktureringskostnader var 8,8 prosent. Ordrereserven endte på 445 millioner euro, en nedgang på 24 prosent sammenlignet med fjoråret og en nedgang på 10 prosent fra foregående kvartal. Peter Nilsson, K

SIKA OPENS MACROFIBER PRODUCTION HUB IN PERU TO MEET FAST-GROWING DEMAND IN LATIN AMERICA25.4.2024 07:00:00 CEST | Press release

SIKA OPENS MACROFIBER PRODUCTION HUB IN PERU TO MEET FAST-GROWING DEMAND IN LATIN AMERICA Sika is opening a state-of-the-art facility in Lima, Peru, to produce synthetic macro fibers, and expanding the rollout of a product range with great growth potential in Latin America. With this innovative technology, Sika is further strengthening its position as a leading supplier to the mining industry and a strong partner for infrastructure projects. Synthetic macro fibers are based on an advanced technology for the constructive and static reinforcement of concrete structures. They reduce construction time and costs by eliminating the need to install conventional reinforcement, while improving the properties of cured concrete. In addition, this innovative technology significantly extends the concrete structures' lifespan compared to steel reinforcement. These factors have a positive sustainability impact on green building ratings such as the international LEED certification system. Mike Campion

Sp Mortgage Bank Plc & Savings Banks Group: Half-Year Reports for January–June 2024 will be published on 14 August 202425.4.2024 07:00:00 CEST | Press release

Stock Exchange Release 25th of April 2024 at 8 am (CET +1) Sp Mortgage Bank Plc & Savings Banks Group: Half-Year Reports for 1st of January–30th of June 2024 will be published on 14th of August 2024 as a stock exchange release and can be also found at www.saastopankki.fi. Sp Mortgage Bank Plc & Savings Banks Group Further information: Karri Alameri Managing Director, Savings Banks Union Coop karri.alameri@saastopankki.fi +358 45 656 5250 Sp Mortgage Bank Plc is part of the Savings Banks Group and the Savings Banks Amalgamation. The role of Sp Mortgage Bank is, together with Central Bank of Savings Banks Finland Plc, to be responsible for obtaining funding for the Savings Banks Group from money and capital markets. Sp Mortgage Bank is responsible for the Savings Banks Group's mortgage-secured funding by issuing covered bonds.

HiddenA line styled icon from Orion Icon Library.Eye